Select Page
Home » Catalent News » Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360

SOMERSET, N.J. – October 24, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it will give two presentations during the “Manufacturing and Bioprocessing Track” at the forthcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 at the Henry B. Gonzalez Convention Center, San Antonio, Texas, on Nov. 3 – 6, 2019.

On Wednesday, Nov. 6 at 10:30 a.m., Lisa Caralli, Director, Science and Technology, will present “Case Studies in Characterizations and Formulation for your Oral Small Molecule Drugs.” Ms. Caralli will advise on methods to analyze physicochemical and biopharmaceutical data to make early drug development decisions. She will explain how to diagnose and address pharmacokinetic issues, and how the application of the developability classification system can guide the design of drug formulations.

Later on Wednesday, at 11:30 a.m., Catalent’s Lun Xin, Process Development Scientist, will present “Mass Spectrometry Tools for Host Cell Protein (HCP) Analysis.” Attendees will learn about the power of mass spectrometry when applied to HCP analysis and characterization, and Mr. Xin will compare mass spectrometry analysis to traditional, enzyme-linked immunosorbent assay (ELISA) and explore its advantages with regards to identifying and quantifying individual species.

Following the presentations, Catalent will host a networking lunch reception at 12:30 p.m.

During the conference, Catalent scientists will also present 10 scientific posters in Exhibit Hall 234. The posters will cover a range of topics including the prediction of solid dispersion technology, a novel method for high-throughput preformulation screening, and methods for relative quantification of N-glycans from a therapeutic monoclonal antibody.

Ms. Caralli has over 27 years of industry experience, and in her role at Catalent, works with pharmaceutical companies to identify the appropriate development pathway for their early development drug candidates. She has previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals, and began her career at the Immune Response Corporation. Ms. Caralli holds a bachelor’s degree in biochemistry from the University of California at Davis, Davis, California.

Mr. Xin is a scientist within the Analytical and Formulation Development Group at Catalent’s facility in Bloomington, Indiana. He has extensive experience in developing biological, biochemical and physiochemical assays for biologics characterization, and is a specialist in high-throughput formulation development.  Mr. Xin received a master’s degree in biotechnology from Northwestern University, Evanston, Illinois and is currently working towards his doctorate degree in pharmaceutical chemistry at the University of Kansas, Lawrence, Kansas.

For more information, please visit https://www.catalent.com/index.php/news-events/events/AAPS-Pharmsci360.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR – richard@nepr.agency

Media Contacts

Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com

Richard Kerns
+44 (0) 161 728 5880
richard@nepr.agency

Notes for Editors

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists, at more than 30 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

 

 

More products. Better treatments. Reliably supplied.™